​What Goes Up, Must Go Higher Yet

Ivan Illán |


At the beginning of this year, 90-Day US Treasury Bills yielded 0.528%. Today, it’s 1.350% - a 155% hike. My forecast (as formally recorded each year with the CFA Society, Los Angeles) targeted 0.972%, by 2017 year-end. Even this aggressive outlook would have been an 84% rate increase. Reality, however, has been stranger than fiction.

Regardless, the lack of precision in my short-term Treasury bill yield forecast doesn’t concern me. The magnitude of the move was the point, and more critical element, of this forecast. The 3-month yield jump was so much more significant than even my extremely aggressive forecast. To me, it spells continued challenges in 2018 for the Federal Reserve, our global money markets, and the velocity of money – none of which bode well for fixed income investors, primarily, and equity investors secondarily.



With all the excitement of being on the precipice of a new tax bill passing this week, I look more towards underlying economic fundamentals to indicate where corporate earnings will go in 2018. It’s becoming abundantly clear that “this time is not different”, as the Fed shifts monetary policy from very accommodative to much more restrictive. As with past monetary policy cycles, the proverbial pendulum must now swing in the opposite direction, and with accumulated force.

How will this effect bank lending? Until long term rates are much higher than short term ones, don’t be too optimistic that banks will be adequately incentivized to lend. After all, they’re currently earning 1.00% on their excess capital reserves. That’s a windfall compared to the current 2-10 Year Treasury Spread of 0.52%.

If banks don’t care about lending, then consumers (who’ve already cut back somewhat) will have less access to finance purchases, which puts further pressure on corporate earnings, as top line revenues sag. On the bright side, business spending has been taking up some of the slack, in anticipation of tax savings.

I usually enjoy having a forecast come to fruition, especially one that no one was publishing at this year’s start. But, this one gives me very little joy, as the complex web of monetary easing must now find its way back to normalization. I think even electro-shock therapy (from what I understand) may provide a more pleasant experience.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.